Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 20
4 104
3 141
2 36
1 21
Curative setting
A 41
C 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 2
Breast Cancer 34
Central Nervous System Malignancies 1
Endocrine Tumours 20
Gastrointestinal Cancers 59
Genitourinary Cancers 54
Gynaecological Malignancies 32
Head and neck cancer 9
Melanoma 21
RET fusion-positive tumours 1
Refractory NTRK fusion–positive cancers 2
Sarcoma 9
Skin Cancers 6
TMB-H solid tumours 1
Thoracic Malignancies 70
dMMR/MSI-H solid tumours 1
Curative setting
Brain Tumours 0
Breast Cancer 7
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 0
Melanoma 11
RET fusion-positive tumours 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 1
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.
Quality of Life Checklist To evaluate ESMO-MCBS score adjustments based on quality of life

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Pooled-analysis) Patients with stage II and III colon cancer Gastrointestinal Cancers Colon Cancer - -
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with resected stage II and III colon cancer Gastrointestinal Cancers Colon Cancer - -
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with resected stage II and III colon cancer Gastrointestinal Cancers Colon Cancer - -
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    5FU/LEV (5-fluorouracil + levamisole) - Levamisole Resected stage III (Dukes stage C) colon cancer Gastrointestinal Cancers Colon Cancer - Intergroup 0035
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Tivozanib - Sorafenib Adult patients with relapsed or refractory advanced RCC following ≥2 prior systemic therapies Genitourinary Cancers Renal cell cancer - TIVO-3
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Enzalutamide ADT (androgen deprivation therapy) Placebo + ADT For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy Genitourinary Cancers Prostate cancer - ARCHES
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Lorlatinib - Crizotinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor Thoracic Malignancies Non-small-cell Lung Cancer ALK+ CROWN
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Sacituzumab govitecan-hziy - Physician’s choice of single agent ChT Treatment for adult patients with metastatic triple-negative breast cancer who received at least two or more prior therapies, at least one of them for advanced disease Breast Cancer Breast Cancer Triple-negative ASCENT
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Nivolumab Cabozantinib Sunitinib First-line treatment of adult patients with advanced RCC Genitourinary Cancers Renal cell cancer - CheckMate-9ER
    1

    PRELIMINARY SCORE

    • OS
      8

    ADJUSTMENTS

    FINAL SCORE

    • F1
      5
    Atezolizumab - Single arm (Phase II) Single-arm study of atezolizumab in patients with locally advanced or metastatic urothelial bladder cancer Genitourinary Cancers Urothelial Carcinoma - IMvigor210 (Cohort 2)
    1

    PRELIMINARY SCORE

    • OS
      8

    ADJUSTMENTS

    FINAL SCORE

    • F1
      5

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.